Related Experiment Video
Updated: Apr 19, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine
1Department of Medical Laboratories, Faculty of Health and Caring Professions, Technological Educational Institute of Athens, Athens, Greece.
Abstract:
Despite advances in breast cancer treatment, mortality from breast cancer is still high. Undoubtedly, novel treatment strategies are needed for chemoprevention of high-risk women and for the treatment of receptor-negative breast cancer. An appealing strategy would be the combination of breast endocrine treatment with salicylates and the other nonsteroidal anti-inflammatory agents (NSAIDs). This systematic review aimed to synthesize evidence on the possible synergistic antitumor effect of breast cancer endocrine treatment with salicylates and the other NSAIDs. Electronic databases were searched with the appropriate search terms. Most of the identified studies investigated the possible synergistic effect of exemestane with celecoxib in different clinical settings including metastatic treatment, adjuvant treatment, ductal carcinoma in situ. The possible synergistic effect of tamoxifen with celecoxib was investigated in one experimental study and the possible synergistic effect of exemestane with aspirin was investigated in another experimental study. Synergistic effect was detected in the majority of the studies. In conclusion, existing limited evidence suggests synergistic interaction of salicylates and the other NSAIDs in the treatment of estrogen responsive breast cancer with clinical implications in the reversal of acquired resistance to breast cancer endocrine treatment and in chemoprophylaxis.
Insights
Combining breast endocrine therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib shows a synergistic antitumor effect. This approach may improve treatment for estrogen-responsive breast cancer and aid in chemoprevention.
Area of Science:
- Oncology
- Pharmacology
Background:
- High breast cancer mortality persists despite treatment advances.
- Novel strategies are needed for chemoprevention and treating receptor-negative breast cancer.
Purpose of the Study:
- To systematically review evidence on the synergistic antitumor effects of combining breast cancer endocrine treatment with salicylates and other nonsteroidal anti-inflammatory drugs (NSAIDs).
Main Methods:
- Systematic review of electronic databases using relevant search terms.
- Analysis of studies investigating exemestane with celecoxib, tamoxifen with celecoxib, and exemestane with aspirin.
Main Results:
- Most studies investigated the combination of exemestane and celecoxib across various clinical settings.
- Synergistic antitumor effects were detected in the majority of the reviewed studies.
- Limited experimental studies explored tamoxifen with celecoxib and exemestane with aspirin.
Conclusions:
- Limited evidence suggests a synergistic interaction between NSAIDs and endocrine therapy for estrogen-responsive breast cancer.
- This combination may have clinical implications for reversing endocrine resistance and for breast cancer chemoprevention.
More Related Videos
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug toxicity: Drug–Drug Interaction
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

